YS BIOPHARMA
YS Biopharma is a global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKAยฎ immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.
YS BIOPHARMA
Social Links:
Industry:
Biopharma Biotechnology Health Care
Founded:
2002-01-01
Address:
Beijing, Beijing, China
Country:
China
Website Url:
http://www.yishengbio.com
Total Employee:
501+
Status:
Active
Contact:
+86 400-659-1155
Email Addresses:
[email protected]
Total Funding:
210.67 M USD
Technology used in webpage:
Domain Not Resolving Euro GoDaddy SSL China Ministry Of Public Security
Similar Organizations
HUTCHMED (China) Limited
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company.
Alpha Biopharma
Alpha Biophama is a clinical stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Bioheng
Bioheng is a high-tech R&D innovation company.
BiondVax
BiondVax is an innovative biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
EOC Pharma Group
EOC Pharma is an integrated biopharmaceutical company.
Mabwell Biotech
Mabwell Biotech is a Chinese innovative biopharmaceutical company.
Mereo Biopharma
Mereo is a new UK-based speciality biopharmaceutical company.
Transcenta
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture.
Current Employees Featured
Founder
Stock Details
Investors List
David (Hui) Shao
David (Hui) Shao investment in Post-IPO Equity - YS Biopharma
Yi Zhang
Yi Zhang investment in Post-IPO Equity - YS Biopharma
C-Bridge Capital
C-Bridge Capital investment in Debt Financing - YS Biopharma
Epiphron Capital
Epiphron Capital investment in Series B - YS Biopharma
F-Prime Capital
F-Prime Capital investment in Series B - YS Biopharma
Superstring Capital
Superstring Capital investment in Series B - YS Biopharma
Yipu Capital
Yipu Capital investment in Series B - YS Biopharma
Haitong International Securities Group
Haitong International Securities Group investment in Series B - YS Biopharma
OrbiMed
OrbiMed investment in Series B - YS Biopharma
Adjuvant Capital
Adjuvant Capital investment in Series B - YS Biopharma
More informations about "YS Biopharma"
LakeShore Biopharma - Crunchbase Company Profile & Funding
Also Known As YishengBio, Yisheng Biopharma, YS Biopharma; Legal Name LakeShore Biopharma Co., Ltd. Stock Symbol NASDAQ:YS ; Company Type For Profit; Contact Email โฆSee details»
Yisheng Biopharma Company Profile | Management and โฆ
Www.yishengbio.com . Contact Information. Headquarters. Biomedical Industrial Park 38 Yongda Daxing Rd, Daxing District, Beijing, 102600, China +86 4006034866. Yisheng Biopharma โฆSee details»
Yisheng Biopharma - Overview, News & Similar companies
Apr 3, 2024 YishengBio is a biopharmaceutical company focusing on discovery, development, manufacturing and commercializat. Jul 19, 2021. en.prnasia.com . Yisheng Biopharma and โฆSee details»
Yisheng Biopharma - Products, Competitors, Financials, Employees ...
๋ซ๊ธฐ GAITHERSBURG, Md., April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to โฆSee details»
YiSheng BioPharma - VentureRadar
Similar Companies: YS Biopharma China n/a YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new โฆSee details»
YishengBio Raises $130 Million in Series B Funding to Accelerate ...
Feb 24, 2021 About YishengBio Co., Ltd. YishengBio Co., Ltd. is a global, fully integrated biopharmaceutical company headquartered in Beijing. The Company is engaged in โฆSee details»
Yisheng Biopharma - LinkedIn
Yisheng Biopharma is a fully integrated innovative biotechnology platform that discovers, develops, manufactures and commercializes new generation of vaccines and therapeutic โฆSee details»
Liaoning Yisheng Biopharma Co., Ltd. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Liaoning Yisheng Biopharma Co., Ltd. of Shenyang, Liaoning. Get the latest business insights from Dun โฆSee details»
YishengBio Raises $130 Million in Series B Funding to Accelerate ...
Beijing, China โ February 24, 2021 โ YishengBio Co., Ltd. (โYishengBioโ, the โCompanyโ) announced today the closing of a US$130 million in Series B funding round. The new โฆSee details»
YishengBio Raises $130 Million in Series B Funding to ... - BioSpace
Feb 24, 2021 YishengBio Co., Ltd. ("YishengBio", the "Company") announced today the closing of a US$130 million in Series B funding round. The new investment was co-led by Oceanpine โฆSee details»
YishengBio Raises $130M in Series B Funding - FinSMEs
Mar 2, 2021 YishengBio Co., Ltd., a Beijing, China-based fully integrated biopharmaceutical company, closed a US$130m Series B funding round. ... cited as a novel vaccine by the World โฆSee details»
Yisheng Bio Raises $40 Million in a Royalty-based Funding from โฆ
Beijing YishengBio completed a $40 million Series C round in a royalty-based transaction with R-Bridge, a division of CBC Group focused on royalty transactions. Founded in 1994, Yisheng โฆSee details»
YishengBio Announces Merger with NASDAQ SPAC Company at โฆ
Sep 30, 2022 Beijing YishengBio will merge with a SPAC vehicle, Summit Healthcare Acquisition, to list on the NASDAQ Exchange at a pre-money equity value of $834 million. Last โฆSee details»
YishengBio Raises $130 Million in Series B Funding to Accelerate ...
BEIJING, Feb. 24, 2021 /PRNewswire/ -- YishengBio Co., Ltd. ('YishengBio', the 'Company') announced today the closing of a US$130 million in Serie... Menu icon A vertical stack of three โฆSee details»
Yisheng Biopharma | CipherBio
Explore Yisheng Biopharma's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Summit Healthcare Closes Business Combination With YS โฆ
Hong Kong โ March 20, 2023 โ Cooley advised Summit Healthcare Acquisition Corp. (Summit Healthcare), a publicly traded special purpose acquisition company, on its business โฆSee details»
Week in Review: YishengBio to List on NASDAQ via SPAC Merger โฆ
Oct 1, 2022 Deals and Financings Beijing YishengBio, a vaccine and biologics company, will merge with a SPAC vehicle to list on the NASDAQ Exchange at a pre-money equity value of โฆSee details»
YishengBio Received Approvals From Philippines and UAE For โฆ
Sep 8, 2022 YishengBio is one of the leading suppliers of human rabies vaccine in Chinese market and its development pipeline includes PIKA Rabies Vaccine, PIKA recombinant COVID โฆSee details»
Chinaโs YishengBio chronicles comeback story in Hong Kong IPO โฆ
Mar 9, 2021 China's YishengBio chronicles comeback story in Hong Kong IPO while plotting big moves in infectious diseases, cancerSee details»
YishengBio Raises $130 Million for Immunomodulating Therapies
Beijing's YishengBio closed a $130 million Series B funding round to develop novel biotherapeutics for cancer and infectious diseases using its novel PIKA® immunomodulating โฆSee details»